<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530318</url>
  </required_header>
  <id_info>
    <org_study_id>TolDec-COMBINEM</org_study_id>
    <secondary_id>2020-000737-41</secondary_id>
    <nct_id>NCT04530318</nct_id>
  </id_info>
  <brief_title>Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis</brief_title>
  <acronym>TolDecCOMBINEM</acronym>
  <official_title>Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Judit Pich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut d'Investigacions Biomèdiques August Pi i Sunyer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to assess properly the clinical efficacy of TolDec therapy by&#xD;
      imaging, clinical and surrogate end-points related with the activity of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our working hypothesis is to make a combination therapy with low-moderate efficacy&#xD;
      immunomodulatory drugs with the aim of increasing efficacy without causing serious adverse&#xD;
      effects such as those associated with the available high-efficacy therapies. Cellular&#xD;
      therapies represent a highly specific treatment aimed to target selective &quot;pathogenic&quot; cells&#xD;
      subsets. Tol-Dec loaded with immunogenic peptides interacts with Ag-specific T lymphocytes&#xD;
      inducing regulatory T cells without affecting other cell subsets leading to a antinflammatory&#xD;
      shift of immunological responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in the number of CUA lesion (mean number of the sum at week 12, 18 and 24).</measure>
    <time_frame>week 12, 18 and 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with any Grade 3 -4 adverse events related to product administration during the study period.</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with any Grade 3 -4 adverse events related to study product.</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any Grade 3 -4 adverse events related to study product.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with any SAE events related to study product.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least one MS relapse during the study period.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of MS relapse at 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first MS relapse during the study period.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the disability progression by Expanded Disability Status Scale (EDSS) at week 24.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the disability progression by Multiple Sclerosis Functional Composite (MSFC) at week 24.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the number of CUA lesion at week 24.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free from CUA lesion, gadolinium-enhancing lesions on T1 MRI and new or enlarged lesions on T2-MRI thought the 24 weeks of study.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the number of Gd-enhancing T1 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in number of new or enlarging T2 lesions by scan (mean number of the sum at week 12, 18 and 24) and at week 24.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in brain global, white and gray matter volume and cervical cord volume on MRI at 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the number of cortical lesions on MRI at 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in MR measurements of diffuse damage of brain tissue by MTR at 24 weeks</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in MR measurements of relaxation times of T1 and T2 by MTR at 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in DTI measures as mean diffusivity (MD), fractional anisotropy (FA), radial diffusivity (Dr) and axial diffusivity (Da) at 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in cytokine production (including IFNgamma, IL-17, IL-4 and IL-10) in response to specific peptide stimulation in peripheral blood mononuclear cells (PBMCs) culture supernatants at 12 and 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in T cell proliferation to immunogenic peptides at 12 and 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in immune cell subsets in PBMCs including PBMC subtypes, T lymphocytes subpopulations and Treg subsets, CD4 and CD8 GM-CSF 'encephalitogenic' T cells and T cell subtypes by activation memory phenotype at 12 and 24 weeks.</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>TolDec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of dendritic cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded</intervention_name>
    <description>The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).</description>
    <arm_group_label>TolDec</arm_group_label>
    <other_name>TolDec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-65 years old.&#xD;
&#xD;
          2. Patients diagnosed with RRMS according to 2017 McDonald criteria.&#xD;
&#xD;
          3. MS disease duration &lt; 10 years.&#xD;
&#xD;
          4. Expanded disability status scale (EDSS) from 0 to &lt; 5.5.&#xD;
&#xD;
          5. Patients eligible to start or already are in on treatment with first line&#xD;
             immunomodulatory treatment (interferon beta 1a, interferon beta 1b, glatiramer&#xD;
             acetate, teriflunomide or dymethyl-fumarate).&#xD;
&#xD;
          6. Able to sign informed consent.&#xD;
&#xD;
          7. Women of child-bearing potential must have a negative pregnancy test in serum before&#xD;
             the inclusion in the study and agree to use highly effective contraceptive methods&#xD;
             during the study. Highly effective contraceptive methods will include: intrauterine&#xD;
             device, bilateral tubal occlusion, vasectomized partner and sexual abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a relapse or use of steroids 30 days prior to screening visit.&#xD;
&#xD;
          2. Concomitant use of any type of immunomodulatory / immunosuppressive therapy.&#xD;
&#xD;
          3. Use of previous immunosuppressive or cytotoxic therapy in the last 6 months. Use of&#xD;
             previous alemtuzumab, cladribine or bone marrow or stem cell transplant at any time.&#xD;
&#xD;
          4. Patients unable or unwilling to undergo MRI scans.&#xD;
&#xD;
          5. Severe systemic diseases or history of cancer or hereditary familiar cancer.&#xD;
&#xD;
          6. Clinically relevant concomitant disease: cardiac, gastrointestinal, hepatic,&#xD;
             pulmonary, neurological, renal or other major disease.&#xD;
&#xD;
          7. Impossibility to proceed to the leukapheresis (e.g. absence of peripheral venous&#xD;
             access).&#xD;
&#xD;
          8. Pregnant or breastfeeding women.&#xD;
&#xD;
          9. Drug or alcohol abuse.&#xD;
&#xD;
         10. Patients with active systemic bacterial, viral or fungal infections, or known to have&#xD;
             AIDS or to test positive for HIV antibody at screening.&#xD;
&#xD;
         11. Ongoing known bacterial, viral or fungal infection (with the exception of&#xD;
             onychomycosis and dermatomycosis), positive hepatitis B surface antigen or hepatitis C&#xD;
             antibody tests at screening.&#xD;
&#xD;
         12. Patients with a known history of syphilis or tuberculosis or test positive for&#xD;
             syphilis (positive rapid plasma reagin, RPR) or tuberculosis (positive skin test) at&#xD;
             screening. Active or latent tuberculosis (TB).&#xD;
&#xD;
         13. Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity&#xD;
             that may interfere with the compliance to the protocol.&#xD;
&#xD;
         14. Any other clinically relevant medical or surgical condition, which, in the opinion of&#xD;
             the investigator, would put the subject at risk by participating in the study.&#xD;
&#xD;
         15. Participation in other experimental studies within the previous 90 days prior to&#xD;
             screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolanda Blanco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yolanda Blanco, MD</last_name>
    <phone>+34932275414</phone>
    <email>yblanco@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Benitez</last_name>
    <email>dbenitezr@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Moisés Broggi</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irati Zubizarreta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucía Romero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Blanco, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Querol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvira Munteis, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Judit Pich</investigator_full_name>
    <investigator_title>Clinical Research Manager. CTU Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

